Forward signals Metabolic disorders, including obesity, diabetes and insulin resistance, continue to rise worldwide,105 and women face distinct metabolic risks, including during pregnancy, menopause and hormonal transitions.106 With increasing awareness of GLP-1 therapies reshaping patient expectations around metabolic care,107 wearable devices and connected platforms, such as CGMs, biosensors and AI- driven analytics, are emerging as complementary technologies that enable prevention and long- term monitoring. Expanding reimbursement for CGM use in gestational diabetes and hypertension, growing payer investment in digital therapeutics and increasing integration of metabolic data with reproductive-health platforms supports adoption. Reasons for optimism –Structural demand: Women’s distinct metabolic profiles create ongoing demand for personalized, longitudinal monitoring and management. –Innovation-driven adoption: Integration of CGM, AI and reproductive-linked insights is driving clinical credibility and engagement. –Coverage and ROI validation: Expanding reimbursement for metabolic conditions, such as gestational diabetes and hypertension, as well as evidence of cost reduction, reinforce investment attractiveness. Point of caution for investors –Need to differentiate from general wellness devices: Success will depend on validated clinical outcomes, payer alignment and integration into chronic-care pathways, rather than consumer-only models. 3.7 Summary As explored in the analysis, each opportunity area aligns conceptually along the two axes – the current level of market activity (scale and diversity) and the strength of forward opportunity signals (future growth and momentum) – illustrating how capital can engage differently across the sector. (See Detailed analysis: Areas prime for investment for a full analysis.) For example, women’s cancer therapeutics and remote maternal health monitoring exemplify the hallmark of emerging, high-growth platforms, but remain fragmented, particularly among dedicated women’s health-specific companies. These markets are still taking shape structurally and present near- term opportunities for early-stage (e.g. venture capital) growth and mid-market PE investors to help build scale and strengthen the evidence needed for broader adoption. Scalable growth leaders, such as women-first longevity clinics and virtual women’s healthcare and benefits management, already exhibit strong capital flows, predictable reimbursement and ecosystem integration. Demand for these models continues to accelerate, supported by payer and employer engagement, making these segments attractive to late-stage investors seeking proven revenue and platform expansion potential. Other categories, such as endometriosis and PCOS, represent catalytic or ecosystem-building opportunities. Despite large, global disease burdens, these areas remain underfunded, with limited market activity and unclear end-points. Blended finance can help generate early evidence and de-risk pipelines, while long-horizon investors can support ecosystem building. Established markets, such as contraceptives and pregnancy testing, represent efficiency plays – large but slow-growth segments well suited to consolidation and operational optimization, particularly in regions where brand portfolios remain fragmented or distribution networks are underdeveloped. Women’s health can be viewed as an interconnected portfolio of evolving opportunities – each at different stages of maturity but collectively advancing towards greater scale, integration and commercial viability. Women’s Health Investment Outlook 30

Womens Health Investment Outlook 2026